Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Innovate (VATE) Consolidated Net Income (2017 - 2025)

Innovate has reported Consolidated Net Income over the past 14 years, most recently at -$7.6 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at -$7.6 million for Q4 2025, up 56.07% from a year ago — trailing twelve months through Dec 2025 was -$64.0 million (down 61.21% YoY), and the annual figure for FY2025 was -$64.0 million, down 61.21%.
  • Consolidated Net Income for Q4 2025 was -$7.6 million at Innovate, up from -$9.6 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for VATE hit a ceiling of $51.9 million in Q1 2021 and a floor of -$200.3 million in Q3 2021.
  • Median Consolidated Net Income over the past 4 years was -$10.6 million (2023), compared with a mean of -$19.5 million.
  • Biggest five-year swings in Consolidated Net Income: crashed 2542.68% in 2021 and later soared 218.8% in 2024.
  • Innovate's Consolidated Net Income stood at -$200.3 million in 2021, then skyrocketed by 94.71% to -$10.6 million in 2023, then plummeted by 63.21% to -$17.3 million in 2024, then surged by 56.07% to -$7.6 million in 2025.
  • The last three reported values for Consolidated Net Income were -$7.6 million (Q4 2025), -$9.6 million (Q3 2025), and -$21.0 million (Q2 2025) per Business Quant data.